The Federal Trade Commission has approved an application by Teva to reopen and modify its decision and order in connection with the 2012 merger of Watson Pharmaceuticals, Inc. and Actavis Inc. The Commission had alleged that the merger might lessen future competition for a number of generic drugs, including the generic version of the abuse-resistant […]